Floatz logo

Ganirelix

Arteriosclerosis Disorder

University of Colorado, Denverprotein_peptideN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Arteriosclerosis Disorder cohort.

Asset / SponsorPhaseRating
Dapagliflozin
University Medical Centre Ljubljana
Phase 4BBB
Glibenclamide
University of Campinas, Brazil
Phase 4BB
Aspirin
Yonsei University
Phase 4BB
Dipyridamole
UMC Utrecht
Phase 4BB
Ranolazine
East Carolina University
Phase 4BB

View all 10 →

Same molecule, other indications

Ganirelix is also rated in:

ovarian cystDormant
BB
Indicative · Phase 4
65 / 100
View asset →
ovarian hyperstimulation syndromeDormant
BB
Indicative · Phase 4
65 / 100
View asset →
polycystic ovary syndromeActive
B
Indicative · Phase 4
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →